Adeno-associated viral (AAV) vectors are a promising method for delivering genes in vivo, but pre-existing neutralizing antibodies (NAb) to AAV proteins present a significant challenge. A thorough understanding of immunogenicity is necessary for effective gene therapies.
Dive deep into the cutting-edge iLite® AAV NAb Assay platform. This powerful tool assesses the neutralization of AAV antibodies and includes AAV production in the same system. It overcomes the challenges of the AAV production step and reduces the steps in cumbersome cell-based AAV NAb assessment assays. Learn how in this whitepaper available for download.